Fulvestrant, a selective estrogen receptor degrader, is approved for treatment of ER positive metastatic BrCa in postmenopausal women. The optimal dosing has been an area for debate; the lower than expected clinical performance in BrCa may be partially explained by inadequate fulvestrant dosing. This study provides evidence that responsiveness to anti-ER therapies such as fulvestrant could be measured by early pharmacodynamic imaging of ER binding/degradation. We demonstrate that 
INTRODUCTION
Estrogen receptor-α (ERα) is expressed in the majority of human breast cancers (BrCa) and is a critical driver of breast tumorigenesis (1, 2) . Therefore, expression of ERα is an important factor in prediction of prognosis and effectiveness of anti-hormone therapy. Patients with ERα-positive (ERα+) tumors typically have longer overall survival and are more likely to respond to hormonetargeted therapies (3) . The expression of ERα is highly variable among BrCa patients and moreover, there is a high degree of heterogeneity found in the level of ERα expression among the metastatic foci in individual patients (4, 5) .
Selective estrogen receptor down-regulators (SERDs) are a relatively new class of drugs for the treatment of ER-expressing BrCa. Fulvestrant, the prototypical SERD, competitively binds ER, disrupts nuclear uptake of ER, and accelerates receptor turnover via the ubiquitin-proteasome pathway (6) (7) (8) . Fulvestrant is currently indicated for the treatment of metastatic breast cancer in postmenopausal women. While its efficacy is well-established in first-and second-line settings, only a fraction of women treated with fulvestrant experience an objective response (9-11). Some hypothesized that the approved dose was suboptimal, spurring trials of different dosing regimens (12) . While limited studies have demonstrated that fulvestrant-induced ER downregulation is dose-dependent, (13, 14) the foray into high-dose regimens proceeded empirically, with a deduced assumption of the level of ER downregulation with fulvestrant therapy and how ER level changes over the course of monthly treatment cycles (15) (16) (17) (18) . The tissues and ERα-positive mammary tumors (20) (21) (22) . The agent focally accumulates at sites of specific overexpression of ERα. The use of 18 F-FES PET as a measure of tumoral ERα expression has been validated in clinical studies (20, 23, 24) . 18 F-FES imaging, in limited studies, has been shown to be of value in prediction of responsiveness to anti-hormone therapy (25) (26) (27) (28) . This radiotracer can be utilized to quantitate the ERα density in BrCa (24, 27 ) and therefore can be used to precisely monitor the effects of any drug that abolishes ERα production, promotes ERα degradation, or that competes with 18 F-FES for ERα binding (29) (Fig.   1 ). Thus, 18 F-FES PET imaging provides an unprecedented opportunity to assess immediate drug efficacy on ER capacity and guide dose selection in individual patients.
The objective in this study was to use the quantitative nature of 18 F-FES PET imaging to monitor the ER that is occupied and/or degraded by fulvestrant (SERD) treatment at a given time, based on changes in the levels of available receptor for 18 F-FES binding. Using another PET radiotracer, 18 F-fluoro-deoxy-glucose ( 18 F-FDG), and a histopathological biomarker of proliferation (Ki-67), we were able to demonstrate the advantage of ERα imaging for early assessment of therapy well before the metabolic and histopathologic effects of treatment can be observed. The concept of ERα imaging for individualized dose adjustment early in the course of treatment has the potential to be readily translated to patients with BrCa to more effectively monitor treatment and improve dosing regimens.
Research. (30) . The mean specific activity of 18 F-FES used in this study was 6.1Ci/μmol (range: 5.4-6.8 Ci/μmol).
Cell culture
Cell lines and culture media were obtained from ATCC (Manassas, VA). The ER-expressing human breast adenocarcinoma cell line, MCF-7, and triple negative human breast adenocarcinoma line, MDA-MB-231, were grown in Dulbecco's Modified Eagle's Medium (DMEM) and Leibovitz's L-15 Medium, respectively. Both media were supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA) and 1% penicillin-streptomycin (Gibco, Life Technologies, Grand Island, NY). All cells were maintained in a humidified incubator at 37°C with 5% CO 2 . The cells were in culture for less than 6 months after resuscitation. Cell lines undergo comprehensive quality control and authentication procedures by ATCC before shipment. These include testing for mycoplasma by culture isolation, Hoechst DNA staining, and PCR, together with culture testing for contaminant bacteria, yeast, and fungi. Authentication procedures used include species verification by DNA barcoding and identity verification by DNA profiling. 
In

Tumor implantation and treatment
Tumor ER expression assays
Extracted xenografts (3 per group) were immersed in ice-cold cellular lysis buffer from the PARIS Kit and disrupted using a rotor-stator homogenizer. Relative ERα protein expression was measured on sandwich ELISA using 20 µg whole cell lysate per well. Non-specific absorbance from a reference wavelength and from diluent-only control were subtracted. RNA was purified from a fraction of the lysate immediately after homogenization and reverse transcription was performed on 150 ng total cellular RNA. qRT-PCR and data processing were performed as described above.
Part of the resected tumor was fixed in 10% neutral buffered formalin for 24 hours and embedded in paraffin. Serial sections in 4 µm-thick slices were used for immunohistochemistry (IHC). For ER assessment, slides underwent heat-induced epitope retrieval (HIER) using citrate-based (pH 6.0) buffer for 15 minutes heated to a maximum of 99°C, followed by incubation with prediluted monoclonal antibody 6F11 (Abcam, Cambridge, MA) (approximately 10 mg/ml). For Ki-67 assessment, separate slides underwent HIER using EDTA-based (pH 9.0) buffer for 20 minutes at 99°C, followed by incubation with monoclonal antibody MIB-1 (Abcam, Cambridge, MA) (1:200). All primary antibodies were incubated for 15 minutes at room temperature and detected using a polymer-based DAB system (Thermo Fisher Scientific Inc., Rockford, IL). Photomicrographs were recorded using the Olympus IX51 microscope equipped with a DP72 camera under consistent magnification (20x), exposure duration, and lighting.
Small-animal PET
For
18
F-FDG-PET only, animals were fasted for at least 4 hours prior to radiotracer injection. F-FES SUV mean was also normalized to blood pool activity at the time of scan from a 3D spherical 3 mm ROI drawn within the heart and 18 F-FES uptake was expressed as target-to-background ratio (TBR).
Statistical analyses
Statistical analysis was performed with Prism software (version 5; GraphPad, La Jolla, CA).
Data from multiple groups were compared by one-way analysis of variance (ANOVA) followed by Holm-Sidak's post hoc multiple comparisons test. For in vitro experiments only, semilogarithmic dose-response data were fit to four-parameter sigmoidal curves. Correlation analysis 
was conducted using Pearson's r. Data are graphed as mean ± standard error of the mean. P values less than 0.05, multiplicity-adjusted when appropriate, were considered significant.
Research. 
RESULTS
In vitro analysis of MCF7 cells
We performed 18 F-FES retention studies after incubating MCF7 cells with serial dilution doses of fulvestrant for 24 hours. Significant dose-dependent changes in 18 F-FES uptake were observed (Fig. 2A) 
Ex vivo analysis of tumor xenografts
Research. In MCF7 xenografts resected 48 h after fulvestrant treatment, nuclear ERα protein expression displayed significant dose-dependent changes with fulvestrant treatment (Fig. 3A; p=0.001).
Compared to vehicle, tumor ERα protein levels decreased by 30.6% (p=0.03), 73.9% (p=0.0015), and 74.9% (p=0.0015) when mice were treated with 0.05 mg, 0.5 mg, and 5 mg fulvestrant, respectively. These changes in protein expression from tumor lysate were confirmed by ER IHC. Qualitative analysis revealed reduced nuclear ER staining intensity and proportion of positive cells in tumors from mice treated with higher fulvestrant doses (Fig. 4A-D) .
Upstream of ER protein expression, dose-dependent changes in ESR1 mRNA expression were not apparent ( Fig. 3B; p=0.39 ). Similarly, treatment was not associated with discernible reductions in staining for the proliferation marker Ki-67 ( Fig. 4E-H ). Most cells in non-necrotic areas of all tumors remained highly positive for Ki-67, indicating little effect on downstream ER function. Together, these data confirm that fulvestrant degrades ER specifically at the protein level in a dose-dependent manner in vivo, and that these changes occur prior to changes in proliferation.
In vivo PET imaging
We assessed whether quantitative molecular imaging with These findings match our findings and indicate that 18 F-FES may be used as a biomarker for fulvestrant efficacy and may help to identify patients that could potentially benefit from a higher dose.
To the best of our knowledge we have demonstrated for the first time that a graded response to fulvestrant can be monitored by 18 F-FES and the magnitude of reduction in radiotracer uptake was concordant with changes in functional ER expression. The reduction in 18 F-FES uptake by xenografts could be largely explained by reduced ER expression due to protein ubiquitination and degradation and/or direct blockade of ER by fulvestrant. We observed a parallel but slightly greater reduction in We demonstrated 18 F-FES uptake highly correlated with ER protein levels but not mRNA expression. It has been shown that ESR1 mRNA robustly correlates with protein expression and holds prognostic significance (35, 36) . However, because SERD therapy uncouples ER protein expression from ESR1 mRNA transcription by specifically degrading ER protein, 18 F-FES makes a better prognostic tool than ESR1 mRNA for functional ER levels in the setting of such targeted therapy.
In this study we observed dissociation between dose-dependent reduction in ER expression and were downregulated with fulvestrant treatment (13, 14, 37) . We used similar doses of fulvestrant given in widespread reports in similar preclinical tumor model (31, 38, 39) . However, in our study, the time between treatment and tumor extraction was much shorter than previous reports and was likely insufficient for ER degradation to affect subsequent downstream metabolic and proliferation pathways. This represents a unique advantage for There are several limitations to this study. First, endocrine therapies that directly block ER (e.g., fulvestrant, tamoxifen, and raloxifene) or diminish ER protein levels (e.g., fulvestrant) both can decrease the F-FES uptake is due to either effect. Second, measuring receptor occupancy levels using 18 F-FES PET is most useful when the receptor-targeted therapies such as tamoxifen or fulvestrant is in the subsaturating range. If the administered dose of anti-estrogen is high enough to completely saturate receptors, then there will be no receptor-specific tracer uptake; in these circumstances, receptor quantitation using PET imaging shows complete occupancy and the degree of excess drug dose cannot be assessed. In practice, the majority of BrCa patients is given subsaturating doses of anti-ER therapy and may benefit from dose adjustment using the proposed approach. Third, the data presented in this study are derived from experiments on a well-established model of ER+ BrCa that is commonly used. Using this model we demonstrated the feasibility of pharmacodynamic imaging for improved fulvestrant dosing. However, since the model we utilized was only derived from MCF-7 cells, generalizing these findings may require further studies with multiple BrCa models.
Research.
on This technology could also be used early in drug development to measure effectiveness at the intended therapeutic targets and to help refine patient selection and dosing levels for agents in drug development. In addition, this image-guided approach to individualized drug dosing may also be employed for other receptor-targeted therapies in cancer treatment in the future. Given the limitations of this study, further study using carefully timed serial 
